Cardiac enzymes are essential indicators in the assessment of heart health, providing valuable insights into cardiac conditions. These enzymes, including myoglobin, creatine kinase-MB (CK-MB), and aspartate aminotransferase (AST), serve as sensitive markers for myocardial damage. Elevated levels of these enzymes in the bloodstream can signal various cardiac issues, such as myocardial infarction or angina. Among them, CK-MB is particularly specific to heart muscle, aiding in the accurate diagnosis of heart-related disorders. The measurement and interpretation of cardiac enzyme levels empower healthcare professionals to make informed decisions, facilitating early detection and intervention in cardiac emergencies. Understanding the nuances of different cardiac enzymes enhances the precision of cardiovascular diagnostics, contributing to more effective patient care.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States